美國藥廠輝瑞及BioNTech正為Omicron病毒製造新疫苗

In Market Shorts
January 26, 2022
COVID-19新變異株Omicron傳染力極強,引發全球疫情再起。美國藥廠輝瑞(Pfizer)與合作夥伴BioNTech 1月25日表示,針對Omicron病毒的新疫苗,已啟動臨床試驗,但可能無法如期在3月上市。路透社報導,輝瑞與BioNTech於美國招募1,400多名志願者,注射針對Omicron變種病毒的疫苗,評估安全性及免疫反應。輝瑞指出,現有研究及數據顯示,第三劑加強針即可降低因Omicron住院和重症的機率,但保護力會隨著時間減弱,加上未來可能出現新的變種病毒,需要為此作好準備。先前,輝瑞執行長博爾拉(Albert Bourla)稱,將開發針對Omicron病毒的新疫苗,可望於3月準備就緒。不過,BioNTech表示,由於需提供充足的臨床試驗資料給衛生主管機關,可能無法按原定計畫在3月底前推出針對Omicron病毒的疫苗。

場外式黃金/白銀交易的風險:
Service relating to Over-the-counter (OTC) Gold Bullion/Silver trading is provided by MOL. OTC Gold/Silver Bullion trading carries a high degree of risk and may not be suitable for all investors. The high degree of leverage can work against you as well as for you. OTC Gold/Silver Bullion is not regulated by the Securities and Futures Commission (""SFC"") and therefore trading OTC Gold/Silver Bullion will not be subject to rules or regulations promulgated by the SFC. Before deciding to trade OTC Gold/Silver Bullion you should carefully consider your investment objectives, level of experience, and risk appetite. The possibility exists that you could sustain losses in excess of your deposited fund or even more in extreme circumstances and therefore, you should not invest money that you cannot afford to lose. You should be aware of all the risks associated with trading OTC Gold/Silver Bullion, and seek advice from an independent financial advisor if you require.